spacer
home > ebr > winter 2003 > streamlining phase i through a successful partnership strategy
PUBLICATIONS
European Biopharmaceutical Review

Streamlining Phase I through a Successful Partnership Strategy

The industry is under increasing pressure to streamline all phases of new drug development and significant emphasis is being placed on the ability of Phase I to identify and 'kill' unsatisfactory candidates quickly and efficiently. At the same time, this phase must arm the winners with not just safety information, but as much efficacy data as possible to help smooth the transition into later-phase clinical trials. These trends have strategic implications not only in the design of studies and programmes, but also in the organisation of R&D and selection of outsourced development partners.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr David Griffiths, Head of Business Development at LCG Bioscience

Dr David Griffiths joined LCG Bioscience as Head of Business Development in 1998, where he has played a pivotal role in creating one of the foremost European CROs specialising in exploratory phase clinical development. David's career began in R&D positions with Shell and Pfizer during which time he obtained a BSc in Applied Biology and a PhD in Drug Metabolism. He then joined a biotech start-up company as a Development Scientist, moving into business development where he was responsible for several successful projects within a fast growing diagnostics and health care group. David also holds an MBA from Anglia Business School, Cambridge.

spacer
Dr David Griffiths
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Registration Opens for Inaugural HPAPI USA Conference in October

The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >>

White Papers

Accelerate Your Database Lock Using Clean Patient Optics

Bioclinica

Because a key step towards database lock is obtaining clean data for all patients, the ability to verify that data are clean early accelerates the ability to lock the clinical database. This ultimately shortens the overall study timeline while ensuring the quality of your data. However, this can be challenging when manually reviewing study data, particularly with larger studies.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement